School of Biological Science, Jining Medical University, Jining, China.
College of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310027, China.
Biomed Pharmacother. 2021 Jan;133:111035. doi: 10.1016/j.biopha.2020.111035. Epub 2020 Nov 17.
Outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 have produced high pathogenicity and mortality rates in human populations. However, to meet the increasing demand for treatment of these pathogenic coronaviruses, accelerating novel antiviral drug development as much as possible has become a public concern. Target-based drug development may be a promising approach to achieve this goal. In this review, the relevant features of potential molecular targets in human coronaviruses (HCoVs) are highlighted, including the viral protease, RNA-dependent RNA polymerase, and methyltransferases. Additionally, recent advances in the development of antivirals based on these targets are summarized. This review is expected to provide new insights and potential strategies for the development of novel antiviral drugs to treat SARS-CoV-2 infection.
严重急性呼吸综合征冠状病毒(SARS-CoV)、中东呼吸综合征冠状病毒(MERS-CoV)和 SARS-CoV-2 的爆发在人类中产生了高致病性和高死亡率。然而,为了满足这些致病冠状病毒治疗需求的不断增加,尽快加速新型抗病毒药物的开发已成为公众关注的焦点。基于靶点的药物开发可能是实现这一目标的有前途的方法。在这篇综述中,突出了人类冠状病毒(HCoVs)中潜在分子靶点的相关特征,包括病毒蛋白酶、RNA 依赖性 RNA 聚合酶和甲基转移酶。此外,还总结了基于这些靶点开发抗病毒药物的最新进展。预计这篇综述将为开发治疗 SARS-CoV-2 感染的新型抗病毒药物提供新的见解和潜在策略。